Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published September 2019 | Supplemental Material
Journal Article Open

An agonist of the MscL channel affects multiple bacterial species and increases membrane permeability and potency of common antibiotics

Abstract

The bacterial MscL channel normally functions as an emergency release valve discharging cytoplasmic solutes upon osmotic stress. The channel opens and passes molecules up to 30 Å and its pore is the largest of any gated channel. Opening the MscL pore inappropriately is detrimental to the bacterial cell, suggesting MscL as a potential novel drug target. A small‐molecule compound, 011A, has been shown to increase sensitivity of the Escherichia coli MscL channel, slow growth, and even decrease viability of quiescent cultures. The mscL gene is highly conserved and found in the vast majority of bacterial species, including pathogens. Here, we test the hypothesis that 011A can influence the growth and viability of other bacterial species, specifically Staphylococcus aureus and Mycobacterium smegmatis, in a MscL‐dependent manner. Furthermore, we demonstrate that the 011A compound can increase potency of other antibiotics, presumably by permeabilizing the membrane and allowing easier access of the antibiotic into the cytoplasm. Thus, MscL activators have potential as novel broad‐spectrum antibiotics or adjuvants that work with antibiotics to selectively allow passage across bacterial membranes.

Additional Information

© 2019 Wiley. Issue Online: 10 September 2019; Version of Record online: 08 June 2019; Accepted manuscript online: 08 June 2019; Manuscript accepted: 06 June 2019. The authors thank Dr. Jan Maarten van Dijl for the generous gift of the S. aureus strains (MscL‐null and parental strain R4220), Linda Millen for assistance in performing and analyzing the toxicity of 011A to HEK293 cells, Dr. Graham Hatfull for plasmids pJV53, Dr. William Jacobs for plasmid pYUB1471 and phage pHAE280, Dr. Glickman for plasmid pDB88, Dr. Annabel Parret and Dr. Matthias Wilmanns for plasmid pMyNT, and Dr. Douglas Rees for overseeing the construction of the generation of the M. smegmatis MC2155 ΔmscL strain and plasmids, and Drs. Philip Thomas and Limin Yang for helpful suggestions and critical reading of the manuscript. This work was supported by Grant GM121780 from the National Institutes of Health, and Grant I‐1420 of the Welch Foundation. N.H. was independently funded by the Howard Hughes Medical Institute Gilliam Fellowship. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funding organizations. Author contributions: R.W. performed of the whole‐cell physiology assays including growth and viability studies. N.H. generated the M. smegmatis ΔmscL strain and M. smegmatisplasmids for this study. J.W. performed the computational analyses including all MD simulations. II helped to analyze, process and present some of the data including the generation of the alignment. II and PB oversaw the whole‐cell physiology experiments and orchestrated the project. All authors contributed to the writing of the manuscript. The authors claim no conflict of interest.

Attached Files

Supplemental Material - mmi14325-sup-0001-supinfo.pdf

Files

mmi14325-sup-0001-supinfo.pdf
Files (1.3 MB)
Name Size Download all
md5:733e811643b4fb029b2746bbbdd576d6
1.3 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 20, 2023